Added to YB: 2018-07-23
Pitch date: 2018-07-23
TPIV [bearish]
Marker Therapeutics, Inc.
+98.41%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Market Cap
$23.8M
Pitch Price
$94.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-1.28
EV/Sales
1.33
Sector
Biotechnology
Category
N/A
Show full summary:
TAPIMMUNE INC TPIV
A summary for this pitch has not been created yet.
Read full article (0 min)